Written by 
The Biden administration’s eleventh hour move to expand Medicare coverage for anti-obesity drugs is likely to be popular among seniors, putting the Trump administration — which would ultimately decide whether to carry out the expansion — in the hot seat. Why it matters: The buzzy class of drugs known as GLP-1 agonists have been hailed […]
